# Combined Use of a Respiratory Broad Panel mPCR and Procalcitonin to Reduce Duration of Antibiotics Exposure in Patients With Severe Community-Acquired Pneumonia

> **NCT03452826** · NA · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 411 (actual)

## Conditions studied

- Community-acquired Pneumonia

## Interventions

- **DEVICE:** Antibiotic therapy according to the result of mPCR (device)

## Key facts

- **NCT ID:** NCT03452826
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-04
- **Primary completion:** 2022-08-05
- **Final completion:** 2023-03-01
- **Target enrollment:** 411 (ACTUAL)
- **Last updated:** 2023-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03452826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03452826, "Combined Use of a Respiratory Broad Panel mPCR and Procalcitonin to Reduce Duration of Antibiotics Exposure in Patients With Severe Community-Acquired Pneumonia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03452826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*